Our lab previously demonstrated the activity of anti-CTLA-4 in the Myc-Cap model [35] and showed that CTLA-4 immunotherapy significantly increased the production IFN-γ by CD8 and CD4 tumor-infiltrating T cells [35]. This evidence concerns the gene CTLA4 and neoplasm.